Table 1. Patient characteristics.
| Number of patients (%) (N = 80) | |
|---|---|
| Age, median (range) | 58 (26–77) |
| Sex | |
| Male | 50 (62.5%) |
| Female | 30 (37.5%) |
| ECOG performance status | |
| 0 | 62 (77.5%) |
| 1 | 18 (22.5%) |
| Primary site of disease | |
| Proximal colon | 16 (20.0%) |
| Distal colon | 33 (41.3%) |
| Rectum | 31 (38.8%) |
| Number of metastatic organs | |
| 1 | 17 (21.3%) |
| 2 | 28 (35.0%) |
| ≥ 3 | 35 (43.8%) |
| Number of previous palliative chemotherapy regimens | |
| ≤ 2 | 33 (41.3%) |
| 3 | 32 (40.0%) |
| ≥ 4 | 15 (18.8%) |
| Disease status | |
| Initially metastatic | 45 (56.3%) |
| Recurrent | 35 (43.8%) |
| Time from metastasis to enroll | |
| Median months (range) | 24 (6–106) |
| Previous chemotherapy agents used | |
| Fluoropyrimidine | 80 (100%) |
| Oxaliplatin | 80 (100%) |
| Irinotecan | 80 (100%) |
| Bevacizumab | 9 (11.3%) |
| Cetuximab (in 45 KRAS WT) | 6 (13.3%) |